drugset / Trial / NCT06046066
A Phase 1 Study of NM6603 in Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
Timeline
- Start
- 2023-08-31
- Primary completion
- 2025-04-25
- Completion
- 2025-04-25
Outcome
Outcome not reported
Stopped (Business): “Discontinuation based on a strategic sponsor decision, not driven by safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NM6603 | Small molecule | — | Oral |
Indications
No indication recorded.